These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27347115)

  • 21. Improved ticagrelor antiplatelet effect on discontinuation of phenytoin.
    Weeks P; Sieg A; Vahdat K; Raissi F; Nathan S
    Ann Pharmacother; 2014 May; 48(5):644-7. PubMed ID: 24477376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
    Barillà F; Pelliccia F; Borzi M; Camici P; Cas LD; Di Biase M; Indolfi C; Mercuro G; Montemurro V; Padeletti L; Filardi PP; Vizza CD; Romeo F;
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18(1):1-9. PubMed ID: 27635937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful Treatment of Iatrogenic External Iliac Artery Perforation With Covered Stent: Case Report and Review of the Literature.
    Awan MU; Omar B; Qureshi G; Awan GM
    Cardiol Res; 2017 Oct; 8(5):246-253. PubMed ID: 29118889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
    Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
    Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perioperative management of dual anti-platelet therapy.
    Webster TD; Vaishnava P; Eagle KA
    Hosp Pract (1995); 2016 Dec; 44(5):237-241. PubMed ID: 27846735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction.
    Altıntaş B; Altındağ R; Bilge Ö; Baysal E; Öztürk Ö; Yaylak B; Ede H; Karahan MZ; Burak C; Tanboğa İH
    Int J Cardiol; 2019 Jul; 287():19-26. PubMed ID: 30979602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?].
    Vatankulu MA; Tasal A; Erdoğan E; Göktekin Ö
    Turk Kardiyol Dern Ars; 2012 Apr; 40(3):265-8. PubMed ID: 22864325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor.
    Verdoia M; Rolla R; Negro F; Tonon F; Pergolini P; Nardin M; Marcolongo M; De Luca G;
    Nutr Metab Cardiovasc Dis; 2020 Feb; 30(2):292-299. PubMed ID: 31780401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms.
    Narata AP; Amelot A; Bibi R; Herbreteau D; Angoulvant D; Gruel Y; Janot K
    Neurosurgery; 2019 Jan; 84(1):77-83. PubMed ID: 29490066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Daffara V; Pergolini P; Rolla R; Marino P; Bellomo G; Carriero A; De Luca G;
    Vascul Pharmacol; 2017 Aug; 93-95():42-47. PubMed ID: 28433569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Tonon F; Kedhi E; Suryapranata H; Carriero A; De Luca G;
    J Thromb Thrombolysis; 2019 Oct; 48(3):413-421. PubMed ID: 31065927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
    Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C
    Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
    Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
    Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G
    Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
    Takahashi K; Serruys PW; Chichareon P; Chang CC; Tomaniak M; Modolo R; Kogame N; Magro M; Chowdhary S; Eitel I; Zweiker R; Ong P; Ottesen MM; Tijssen JGP; Wykrzykowska JJ; de Winter RJ; Garg S; Stoll HP; Hamm C; Steg PG; Onuma Y; Valgimigli M; Vranckx P; Carrie D; Windecker S
    J Am Coll Cardiol; 2019 Oct; 74(16):2015-2027. PubMed ID: 31623758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of multi-detector computed tomography for percutaneous coronary intervention in a patient with type V dual left anterior descending artery.
    Yokokawa T; Watanabe K; Sakamoto T; Ohwada T; Takeishi Y
    J Cardiol Cases; 2012 Oct; 6(4):e100-e102. PubMed ID: 30546721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
    Vranckx P; Valgimigli M; Windecker S; Steg PG; Hamm C; Jüni P; Garcia-Garcia HM; van Es GA; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1239-1245. PubMed ID: 26606735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.